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Abstract
Background: Concerns about the hepatitis C virus (HCV) are due to the high risk of chronic liver disease and poor 
treatment efficacy. Synthesizing evidence from multiple data sources is becoming widely used to estimate HCV-
infection prevalence. This paper aims to estimate the prevalence of HCV infection, and the hepatic and extrahepatic 
sequelae in at-risk groups, using routinely collected data in the Lazio region, Italy.
Methods: HCV laboratory surveillance and dialysis, hospital discharge, and drug-user registers were used as 
information sources to identify at-risk groups and to estimate HCV prevalence and sequelae.
Full name and birth date were used as linkage keys for the various health registries. Prevalence was estimated as the
percentage of cases within the general population and the at-risk groups, with 95% confidence intervals (95% CI)
from 1997 to 2001. The risk of sequelae was estimated through a follow-up of hospital discharges up to December 31,
2004 and calculated as the prevalence ratio in HCV-positive and HCV-negative people, within each at-risk group, with
95% CI.
Results: There were 65,127 HCV-infected people in the study period; the prevalence was 1.24% (95%CI = 1.23%-1.25%) 
in the whole population, higher in males and older adults. Drug users (35.1%; 95%CI = 34.6-35.7) and dialysis patients 
(21.1%; 95%CI = 20.2%-22.0%) showed the highest values. Medical procedures with little exposure to blood resulted in 
higher estimates, ranging between 1.3% and 3.4%, which was not conclusively attributable to the surgical procedures. 
Cirrhosis, hepatocellular carcinoma and encephalopathy were the most frequent hepatic sequelae; cryoglobulinaemia 
and non-Hodgkin's lymphoma were the most frequent extrahepatic sequelae.
Conclusions: Synthesising data from multiple routine sources improved estimates of HCV prevalence and sequelae in 
dialysis patients and drug users, although prevalence validity should be assessed in survey and sequelae need a well-
defined longitudinal approach.
Background
Concerns about the impact of the hepatitis C virus
(HCV) have arisen from a few very important issues.
HCV infection is the most frequent cause of chronic liver
disease: up to 85% of infected people have chronic hepati-
tis [1]; 20% develop hepatic cirrhosis and 1%-4% per year
develop hepatocellular carcinoma (HCC) [2]; 20-30% of
liver transplants are performed on chronic hepatitis
patients [1]; 74-86% of infected people develop persistent
viraemia [2], which increases the probability of transmit-
ting the infection. In spite of the recent availability of
drugs that completely eliminate the virus in up to 46% of
cases [3], mortality associated with HCV infection
increases even in industrialized countries [4,5], due to the
difficulty in diagnosing first infections and the poor treat-
ment efficacy. No vaccine and no post-exposure prophy-
laxis are available, therefore studying the risk factors
aimed at primary prevention is an essential tool to con-
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trol HCV infection, as the experience of blood transfu-
sions has shown [6].
After blood screening was introduced, intravenous
drug users show the highest prevalence (58% in the US,
79% in the UK) [7,8], followed by dialysis patients (10%-
36% in USA and 2%-63% in Europe) [9], transplant
patients (9%-33%) [10,11], and patients who underwent
surgical procedures [12]. Vertical transmission during
childbirth occurs from about 3% to 8% of infected moth-
ers [6,13]. There is no definite evidence of sexual trans-
mission [14,15]. Other exposures reported in the
literature, such as, professional exposure [6] and under-
going medical procedures such as endoscopy, intravenous
injections and even autologous transfusion [16-18], sug-
gest that infection is possible even with limited bleeding,
though associated with very low prevalence or sporadic
occurrence.
Adult age at infection, male gender, alcohol consump-
tion and HIV-1 or HBV co-infection are the factors most
frequently associated with the chronic sequelae of the
disease [2,6]. Viral genotype 1b is twice as frequent in cir-
rhosis and hepatocellular carcinoma than other geno-
types [19]. The role of other factors such as obesity is not
consistently supported [20].
Cryoglobulinaemia and non-Hodgkin's lymphoma are
the most frequently reported extrahepatic diseases asso-
ciated with HCV infection; B lymphocyte lymphoma is
reported in 5%-8% of cases [21]. Among the more recent
extrahepatic disorders diabetes and autoimmune thy-
roiditis emerged [21,22]. Other extrahepatic disorders
have also been reported, but without sufficient confirma-
tion [20,21].
Prevalence is the indicator most frequently used to esti-
mate HCV infection in the population, since the silent
onset of HCV infection in most cases makes new infec-
tions very difficult to diagnose [1]. Prevalence offers the
advantage of estimating the burden of chronic liver dis-
ease due to HCV, but the epidemiological characteristics
of HCV infection require laboratory testing, which makes
estimating prevalence in large populations difficult. Syn-
thesizing evidence from multiple data sources into one
model is becoming widely used to estimate hepatitis C
prevalence [23].
In this paper, the prevalence of HCV infection and the
risk of developing hepatic and extrahepatic sequelae for
HCV-infected people within at-risk groups, were esti-
mated synthesising routine data from multiple sources in
a region of Central Italy.
Methods
Study population
Subjects were residents of Lazio, an Italian region with a
population of 5,255,028, which includes the city of Rome.
Groups at-risk of HCV infection were defined as dialysis
patients, drug users referred to drug treatment services
and patients who underwent transfusion, other surgical
procedures or transplants between 1 January 1997 and 31
December 2001. Patients who underwent liver transplant
and dialysis patients who underwent renal transplant
were excluded; those who needed subsequent dialysis
were then re-entered in the study as newly exposed peo-
ple.
Demographic data including age, residence and at-risk
conditions came from the health registries.
Details of at-risk group definitions and sources of data
for at-risk groups are reported in additional file 1, box 1
and 2, respectively. Patients reported in the regional
cause mortality registry (CMR) as having died by 31
December 1996 were excluded.
Human subjects did not participate in the study since
only administrative databases were used. On the other
hand, our department had been commissioned formally,
by the Lazio regional council, to manage the nominative
data of infectious disease surveillance, at the time of this
study, in accordance also with privacy laws enforced in
Italy.
Estimate of HCV infection prevalence
People were defined as HCV-infected if they were
r e p o r t e d  t o  l a b o r a t o ry  s u rv e i l l a n c e  a s  p o s i t i v e  t o  l e a s t
one enzyme immunoassay (EIA) [7], or were discharged
from hospital with a diagnosis of HCV infection, or were
reported to the dialysis registry or to the drug-user sur-
veillance as HCV-infected, even if laboratory test results
were not available. Additional file 1, box 3, reports details
about HCV definition, including ICD-9-CM codes and
characteristics of laboratory surveillance and Hospital
Discharge Registry (HDR).
Subjects reported in more than one registry and those
who underwent more than one invasive procedure were
analysed within each individual at-risk group.
Prevalence of HCV infection has been estimated as the
percentage of cases in the general population and in each
at-risk group with 95% confidence intervals (95%CI), for
the period 1997-2001, using the population at the middle
of the study period as the denominator. Prevalence was
estimated also by gender, age and year using the popula-
tion at the beginning of each year as denominator. Preva-
lence was estimated in drug users as a whole group, in
injectors and in non- injectors.
Underreporting from laboratories was estimated
assuming that laboratories that reported no HCV infec-
tion detected a number of HCV infected people equiva-
lent to the mean number reported by their laboratory
type. Laboratory compliance by category was: 88% (out of
108) of hospitals, 94% (out of 18) of universities, 72% (out
of 43) of outpatient clinics, 39% (out of 148) of private
hospitals, 31% (out of 400) of private laboratories. TheFaustini et al. BMC Infectious Diseases 2010, 10:97
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mean number of HCV-infected people was 420 from hos-
pitals, 104 from universities, 32 from outpatient clinics,
60 from private hospitals and 98 from private laborato-
ries. Subsequently, the expected number of infections
were estimated by adding the products of the percentage
of non-compliant laboratories and the mean number of
infected people in each category to the observed data.
Prevalence trends have been explored only for dialysis
patients and drug users. The relative contribution to the
prevalence of both new cases and deaths was analysed. A
proxy of incidence for these at-risk groups was estimated
as the percentage of new HCV diagnoses, by year. Inci-
dence was estimated in these groups thanks to the initial
and repeated tests subjects underwent during their fre-
quent diagnostic or therapeutic visits. Mortality rates
were estimated in dialysis patients and drug users using
data from the regional cause mortality registry.
Estimates of sequelae
A more specific definition of HCV-positive patients was
adopted to estimate sequelae than to estimate prevalence,
since the former requires that HCV-infected people have
at least one positive laboratory test (immunoassay (EIA),
immunoblot test or PCR test for HCV-RNA) reported to
the laboratory surveillance system, complete with the test
date. Sequelae were studied only in the at-risk groups that
showed a higher prevalence of HCV-infection than in the
general population. Hepatic [1,2] and extrahepatic
[1,2,20,21,24] diseases were analysed as possible sequelae
of HCV infection for each at-risk group by individually
linking the at-risk group files and the hospital discharge
registry (HDR). Diseases were hypothesised to be a con-
sequence of viral infection if it was detected during or
before the same hospitalisation at which the sequelae
were diagnosed.
The hepatic diseases included cirrhosis, gastrointesti-
nal haemorrhage, haemorrhage due to esophageal
varices, liver failure, hepatocellular carcinoma, encephal-
opathy, portal hypertension. The extrahepatic diseases
we considered were cryoglobulinaemia, polyarteritis
nodosa, arthritis in psoriasis, pulmonary fibrosis, non-
Hodgkin's lymphoma, diabetes, cutaneous porphyria,
lichen planus, Sjögren syndrome, Moorhen corneal ulcer,
Reynaud's syndrome, Graves' illness, Hashimoto's thy-
roiditis. Details about ICD-9-CM codes used to define
sequelae are reported in the additional file 1, box 3. The
sequelae were assessed by means of a follow-up using the
discharge diagnoses reported in the hospital files. The
follow-up for detecting sequelae ended on December
31st, 2004, ranging from 3-8 years per patient.
The relative risk of each sequela was estimated using
the prevalence ratio of the specific sequela between
HCV-positive and HCV-negative people, and the 95% CI,
stratified by at-risk group, from 1997 to 2001.
Initially both the complete name and date of birth were
used as linkage keys of the various health registries, and
afterwards only the name.
We carried out all the record-linkage between data files




There were 65,127 people reported as HCV positive;
HCV prevalence in the general population was estimated
at 1.24% (95%CI = 1.23-1.25%). It was higher in males
(1.45%) than in females (1.04%), and infected males
tended to be younger (mean age = 48 yrs) than infected
females (mean age = 57 yrs). There was an estimated
underreporting of 16,974 (26.1%) HCV-positive people,
which increased the estimate of HCV prevalence to
1.56%.
Thirty-six percent of the 65,127 HCV-infected people
belonged to a hypothesised at-risk group.
The highest HCV prevalence was found in drug users
(35.1%; 95%CI 34.6-35.7) and dialysis patients (21.1%;
95%CI 20.2-22.0) (table 1). Injectors were the most fre-
quent type of drug users (81%) and presented the highest
prevalence (42.1%; 95%CI 41.4-42.7). Non- injector drug
users showed a slightly higher prevalence than the gen-
eral population (5.6%; 95%CI 5.0-6.3), suggesting a mis-
classification of exposure or a life style however linked
with a higher risk of HCV infection. The infected drug
users were among the youngest exposed subjects (mean
age = 33.6 yrs), along with females who underwent
obstetric surgery (mean age = 32.1 yrs) and those who
underwent an appendicectomy (mean age = 37.9 yrs).
Among the patients who underwent invasive medical
procedures, those who underwent kidney transplants or
blood transfusions or digestive system surgery or
gynaecological surgery had a slightly higher prevalence
than in the general population but the mean age of
infected people showed very high values in these groups.
Women who underwent obstetric surgery, including
deliveries, and those who underwent an appendicectomy
presented a notably lower risk of infection; infected peo-
ple in both these groups were younger than those who
had gynaecological surgery and digestive system surgery,
respectively. Age-specific prevalence increased steadily
with age for patients who underwent abdominal or
gynaecological surgery, but different patterns were
observed in at-risk groups with high exposure to blood.
Prevalence was higher in 25-74 year-old dialysis patients
than in those younger or older, and was higher in 25-54
year-old transfused patients and drug users.
No gender differences were found for HCV infection
prevalence in dialysis patients, or in transfusion or trans-
plant patients. The higher prevalence of HCV infection inFaustini et al. BMC Infectious Diseases 2010, 10:97
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Table 1: Characteristics of the study population and prevalence of HCV infection in at-risk groups by age, gender and year, 
Lazio, 1997- 2001
drug users blood surgery patients allogenic transplant patients
dialysis not transfus digestive append gynae- lungs bone
patients all injectors injectors patients system ectomy cological obstetr heart marrow kidney
Subjects No. 8562 29,756 24101 5472 20,841 212,983 32,384 96,480 217,776 127 401 679
% males 60.1 86.4 85.3 90.8 48.3 60.6 46.8 56.7 52.9 61.0
mean age 
(yrs)
64.0 32.2 32.6 30.5 67.8 57.4 25.0 47.8 31.0 32.6 34.2 39.8






1807 10,459 10137 307 1001 7237 270 1251 1342 3 11 52
mean age 
(yrs)
62.5 34 33.6 34.4 64.7 62.1 37.9 53.7 32.1 42.1 37.5 42.6
SD 15.5 7 6.6 9.1 17.0 14.9 22.0 14.1 5.6 29.9 15.0 12.0
prevalence % 21.1 35.1 42.1 5.6 4.8 3.4 0.8 1.3 0.6 2.4 2.7 7.7
95% CI 20.2-22.0 34.6-35.7 41.4-42.7 5.0-6.3 4.5 - 5.1 3.3 - 3.5 0.7 - 0.9 1.2 - 1.4 0.5 - 0.6 0.5 - 6.7 1.4 - 4.9 5.8 - 9.9
by age (yrs)
<15 13.1 2.4 4.6 2.9 1.4 1.4 0.7 0.4 1.4 0 1.6 5.0
15-24 14.6 17.1 26.8 2.9 2.0 2.0 0.8 0.5 0.5 7.7 0 1.5
25-34 22.5 34.2 40.0 4.6 7.1 7.1 1.9 0.9 0.6 0 3.9 6.5
35-54 24.7 43.8 49.0 10.6 7.2 7.1 2.7 1.2 0.8 0 3.8 9.0
55-74 22.2 11.9 23.1 4.0 5.1 5.1 3.9 2.8 5.9 3.3 2.3 9.0
75+ 1 7 . 8 000 3 . 9 3 . 9 4 . 4 3 . 5 0000
by genderFaustini et al. BMC Infectious Diseases 2010, 10:97
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female drug users was entirely due to IVDU and may be
explained by the greater frequency with which females
were tested.
Laboratory surveillance made it possible to detect 314
(17.4%) more HCV cases among dialysis patients than
reported in the dialysis register and 3220 (30.8%) more
drug users with HCV than reported in the drug-user sur-
veillance, but 700 (38.7%) infections in the former group
and 4450 (42.5%) in the latter were not confirmed by
available laboratory data. Laboratory surveillance identi-
fied an 88.6% HCV prevalence in transfusion patients and
up to 90% in those who underwent abdominal (90.9%) or
gynaecological surgery (93.8%).
The trend of HCV prevalence decreased in drug users
(p = 0.001) (figure 1) as well as in dialysis patients (p =
0.002) (figure 2) in the period 1997-2001, with an impor-
tant reduction of 2.8% and 2.4% in the prevalence rate by
year, respectively. The decreasing prevalence in dialysis
patients (table 1 and figure 2) might be partly explained
by fewer new HCV diagnoses (incidence decreased from
25.9% to 11.9% in the whole period) and, to a greater
extent, by the increase in mortality of HCV-infected
patients (from 8.9% in 1997 to 19.0% in 2001). A different
scenario is suggested for prevalence trends in drug users
(table 1 and figure 1). Although mortality increased in the
study period for HCV-infected drug users (from 1.1% to
1.9%), the lower number of new cases explains most of
the decreasing prevalence (ranging from 18.9% in 1997 to
7.4% in 2001).
The prevalence decreased in patients with digestive
surgery (p = 0.01) and gynaecological surgery (p = 0.04)
as well (table 1), but with a reduction as small as 0.1 a
year. No trend was apparent for transfusion patients, who
showed similar prevalence rates over five years. No trend
was evident for transplant patients either, who showed a
h i g h l y  v a r i a b l e  p r e v a l e n c e  i n  t h e  p e r i o d  u n d e r  s t u d y
(table 1). We investigated the spatial and temporal vari-
ability of HCV positivity among transplant patients, by
hospital and year. For lung/heart or bone marrow trans-
plants we found no differences with respect to the
hypothesis that the events were casually distributed.
However, most HCV infections in kidney transplant
patients were observed in two large hospitals that per-
formed 16 and 18 transplants respectively, 50% of HCV
infections from kidney transplants were detected in 1997
and three transplants were performed in the same hospi-
tal in the same month of the year.
Sequelae of HCV infection
The sequelae of HCV infection were studied for 16,671
people (72% of the total 23,432) who had a positive HCV
laboratory test and belonged to at least one of the at-risk
groups showing a HCV prevalence higher than the gen-
eral population: dialysis patients, drug users, transfusion
patients and those who underwent digestive system sur-
male 20.9 34 41.8 5.6 5.4 3.5 1.1 2.8 2.4 8
female 21.5 42.5§ 47.8 6.2 4.3 3.2§ 0.56§ 1.3 0.6 1.8 3.2 7.2
by year
1997 32.1 45.8 49.9 7.7 2.3 2.9 1.2 0.5 2.7 3.9 9.1
1998 30.2 42.3 47.4 6.4 3.3 2.7 1 0.4 03 . 1 1 . 4
1999 26.5 39.4 45.3 6.1 2.8 2.7 1.1 0.5 3 . 807 . 7
2000 24.3 36.8 43.2 5.5 2.4 2.5 0.9 0.5 00 1 . 9
2001 23.1 34.6 41.6 5.6 3.2 2.4 0.9 0.5 06 . 5 8 . 3
p-value for 
trend
0.002 0.001 0.001 0.03 0.6 0.01 0.04 0.6 0.1
§ statistically significant (p < 0.05)
Table 1: Characteristics of the study population and prevalence of HCV infection in at-risk groups by age, gender and year, 
Lazio, 1997- 2001 (Continued)Faustini et al. BMC Infectious Diseases 2010, 10:97
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gery or gynaecological surgery. We did not assess seque-
lae in transplant patients due to the low number of HCV-
infected people (table 2).
Hepatic diseases occurred more frequently in HCV-
infected than in HCV-negative people in each of the five
groups reported in table 2. The highest prevalence ratios
were observed in females who underwent gynaecological
surgery (PR = 9.8; 95%CI = 7.4-12.7) and in drug users
(PR = 4.6; 95%CI = 4.0-5.3). Cirrhosis, hepatocellular car-
cinoma, encephalopathy and portal hypertension were
the most frequent hepatic sequelae. Among the extrahe-
patic diseases (table 2), cryoglobulinaemia showed the
highest prevalence ratio in each of the five groups, while
non-Hodgkin's lymphoma was not associated with HCV
infection in dialysis or transfusion patients. No signifi-
cant associations or consistencies between the at-risk
groups were observed for other diseases. Complete data
for extrahepatic diseases were reported in the additional
file 2. The prevalence ratio of hepatic disease increased
with age (results not shown), apart from transfusion
patients (table 1); the prevalence ratio of extrahepatic
sequelae was not associated with the age of infected peo-
ple (table 1).
Discussion
Prevalence estimates and characteristics of HCV infection 
in the at-risk groups
The HCV prevalence (1.24%) observed in our population
is consistent with the estimates of 1.6% reported in the
USA [7], 1.3% reported in European countries [25] and
1.3% reported in blood donors in Italy [26], notwithstand-
ing the possible underestimation discussed below in the
limitations section.
That the highest prevalence is observed in drug users,
dialysis and transfusion patients who had large or
repeated direct exposures to blood, has already been
Figure 1 HCV prevalence, incidence and mortality in drug users, Lazio 1997 - 2001. Black triangle = HCV prevalence St. Andrew's cross = new 
HCV diagnoses. White square = mortality in HCV - Black square = mortality in HCV + Y left axis = HCV prevalence (%) and incidence (%) in drug users. 
Y right axis = mortality (%) in drug users.Faustini et al. BMC Infectious Diseases 2010, 10:97
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r eport ed in most west ern c oun tries [3]. T he very high
prevalence, the highest prevalence in young-adults and
similar or even higher prevalence in females confirm that
these groups are at high risk of HCV infection and define
characteristics of HCV infection in these groups that are
different from those seen in the general population. Thus,
though prevalence was also higher in patients who have
undergone surgical procedures with little exposure to
blood, these patients showed steadily increasing preva-
lence with age and higher prevalence in males suggesting
a connection with age instead of with the medical proce-
dures themselves. The lower prevalence observed in
patients who had an appendectomy or obstetric surgery
supports this hypothesis, since they were younger than
those who underwent digestive system surgery or
gynaecological surgery, whereas the procedures and the
surgery scenarios were essentially comparable. The pat-
terns of age-specific prevalence in dialysis patients, drug
users and transfusion patients suggest a possible cohort
effect with the most HCV transmission occurring in the
last 20-40 years, as reported in the US [27] and in Austra-
lia [28].
HCV prevalence estimates in children are based on the
limited data reported in the literature. A prevalence of
0.2% was reported in 6-11-year-old children in the US in
1999 [29]. HCV-infected children in this study were more
likely to have parents who were drug users than any other
direct exposure. One hypothetical interpretation of these
results involves the vertical transmission of HCV infec-
tion, whose estimate ranges from 3% to 8% [6]. IVDU and
transfusion are the most frequent exposures reported in
the literature in HCV-positive mothers [13,30], but these
estimates usually refer to very young children or those
surveyed for HIV infection. The older age of the children
(up to 14 years) observed here suggests a possible role of
living with HCV-positive parents; testing this hypothesis
requires specifically designed studies.
The high HCV prevalence in patients who underwent
allogenic bone marrow or kidney transplants, the high
risk in the youngest patients, and the prevalence fluctua-
tions from year to year suggest that in our region,
although the prevalence rates were much lower than the
11-33% reported in the literature [10,11], HCV infections
occurred during the transplant procedures. Kidney trans-
plant patients showed the highest values, and possible
hospital clusters were observed for these patients. The
high rates of HCV infection among transplant candidates
[31], the long duration of dialysis and the high doses of
immunosuppressants administered after transplant have
been reported as the most frequent risk factors for HCV
infection [10]. Unfortunately, having observed possible
hospital clusters is not sufficient to assess whether infec-
tion occurred during or before the transplant itself. A
prospective survey of transplant patients could help
resolve this issue. The HCV prevalence of 20-30%
reported in the literature [1] in candidates for liver trans-
plant led us to exclude liver transplant as an exposure
variable.
Figure 2 HCV prevalence, incidence and mortality in patients on dialysis, Lazio 1997-2001. St. Andrew's cross = HCV prevalence White circle = 
new HCV diagnoses. White square = mortality in HCV - Black square = mortality in HCV +. Y axis = HCV prevalence, incidence (%) and mortality (%) in 
patients on dialysis.Faustini et al. BMC Infectious Diseases 2010, 10:97
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Table 2: Prevalence and prevalence ratios of hepatic and extra-hepatic sequelae in HCV+ and HCV- by at-risk group, Lazio 
1997-2001
patients to dialysis† drug 
users §
injector drug users §
HCV + HCV - ratio 95% CI HCV + HCV - ratio 95% CI HCV + HCV - ratio 95% CI
N 1107 7455 6009 23747 5755 18346
% 100 100 100 100 100 100
hepatic 120 451 447 382 427 309
diseases 10.4 6.1 1.8 1.5 - 2.2 7.4 1.6 4.6 4.0 - 5.3 7.4 1.7 4.4 3.8 - 5.1
Cirrhosis 48 95 389 266 370 218
4.3 1.3 3.4 2.4 - 4.9 6.5 1.1 5.8 4.9 - 6.8 6.4 1.2 5.4 4.6 - 6.4
Gastric 73 339 83 87 81 66
hemorrhage 0.3 4.6 1.5 1.1 - 1.9 1.4 0.4 3.8 2.8 - 5.1 1.4 0.4 3.9 2.8 - 5.5
Hemorrhage
due to eso- 3 13 25 12 13 10
phageal varix** 0.3 0.2 1.6 0.3 - 5.7 0.4 0.1 7.6 3.7 - 16.2 0.2 0.1 4.1 1.7 - 10.6
Liver failure 10 37 43 58 43 46
0.9 0.5 1.8 0.8 - 3.7 0.7 0.2 2.9 1.9 - 4.4 0.7 0.3 3.0 1.9 - 4.6
Hepato cellular 4 6 17 7 15 6
carcinoma 0.4 0.1 4.5 0.9 - 18.9 0.3 0.03 9.6 3.8 - 27.4 0.3 0.03 8.0 2.9 - 25.1
Hepatic 9 17 105 56 101 46
encephalopathy 0.8 0.2 3.6 1.4 - 8.5 1.7 0.2 7.4 5.3 - 10.4 1.8 0.3 7.0 4.9 - 10.1
Portal 5 6 27 22 24 18
hypertension 0.5 0.1 5.6 1.4 - 22.1 0.4 0.1 4.9 2.7 - 8.9 0.4 0.1 5.3 2.7 - 10.3
extra-hepatic 15 58 55 48 51 32Faustini et al. BMC Infectious Diseases 2010, 10:97
http://www.biomedcentral.com/1471-2334/10/97
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diseases 1.4 0.8 1.7 0.9 - 3.1 0.9 0.2 4.5 3.0 - 6.8 0.9 0.2 5.1 3.2 - 8.2
Cryoglobuli- 6 4 18 8 17 8
naemia†† 0.6 0.1 10.1 2.4 - 48.7 0.3 0.03 8.9 3.7 - 23.6 0.3 0.04 6.8 2.8 - 18.1
Non-Hodgkin 2 14 25 19 23 15
lymphoma 0.2 0.2 1.0 0.1 - 4.2 0.4 0.1 5.2 2.8 - 10.0 0.4 0.1 4.9 2.4 - 10.1
female reproductive
transfusion digestive system surgery organs surgery
HCV + HCV - ratio 95% CI HCV + HCV - ratio 95% CI HCV + HCV - ratio 95% CI
N 1001 19840 7237 205746 1251 95293
% 100 100 100 100 100 100
hepatic 327 3418 2120 14661 65 506
diseases 32.7 17.2 1.9 1.7 - 2.1 29.3 7.1 4.1 3.9 - 4.3 5.2 0.5 9.8 7.4 - 12.7
Cirrhosis 245 996 1912 10031 48 137
24.5 5.0 4.9 4.2 - 5.6 26.4 4.9 5.4 5.2 - 5.7 3.8 0.1 26.7 18.8 - 37.3
Gastric 148 2585 358 4199 14 232
hemorrhage 14.8 13.0 1.1 1.0 - 1.3 5.0 2.0 2.4 2.2 - 2.7 1.1 0.2 4.6 2.5 - 7.9
Hemorrhage
due to eso- 75 292 236 942 5 16
phageal varix** 7.5 1.5 5.1 3.9 - 6.6 3.3 0.5 7.1 6.2 - 8.2 0.4 0.0 23.8 6.8 - 68.0
Liver failure 19 178 127 1597 7 137
1.9 0.9 2.1 1.2 - 3.4 1.8 0.8 2.3 1.9 - 2.7 0.6 0.1 3.9 1.5 - 8.2
Hepato cellular 40 157 468 1520 81 7
carcinoma 4.0 0.8 5.1 3.5 - 7.2 6.5 0.7 8.8 7.9 - 9.7 0.6 0.0 35.9 13.4 - 87.6
Table 2: Prevalence and prevalence ratios of hepatic and extra-hepatic sequelae in HCV+ and HCV- by at-risk group, Lazio 
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Trends of HCV infection in at-risk groups
That reducing the number of new cases contributes more
than mortality does to decreasing HCV prevalence in
drug users suggests the positive role of preventive mea-
sures. The hypothesis that the harm reduction pro-
gramme implemented in our region in 1994 reduced the
number of new HCV infections as well as of HIV-1 has
not been directly evaluated [32] and clashes with the
results observed in a study in which the preventive pro-
gramme reduced HIV-1 prevalence while HCV transmis-
sion continued at high levels [33]. Although a more
recent study [34] found a reduction in HCV prevalence in
people who participated in syringe exchange programs,
these results cannot be regarded as supportive of effective
protection, since they were not obtained from a commu-
nity trial study design. In contrast, the increasing mortal-
ity in HCV positive dialysis patients contributed more
than the decreasing incidence to the prevalence trend
suggesting possible gaps in the control measures during
dialysis. This hypothesis has already been suggested in
our country [31,35]. On the other hand, the absence of a
decreasing trend in transfusion patients since 1997 sug-
gests improving transfusion safety measures, even though
blood screening began in Italy in 1994.
Sequelae of HCV infection
The number of subjects whose sequelae were studied is
smaller than that of subjects considered infected for the
purposes of prevalence estimates: this is because the defi-
nition of HCV-infected subjects we chose for estimating
this outcome is more specific. The temporal sequence
imposed in studying sequelae assured that HCV infection
was present before the disease diagnosis, but did not
allow to define the timing. Defining a time interval con-
sistent with the latency of all the hypothesized sequelae of
HCV infection was impossible because the first infection
is so difficult to detect, the latency period to develop
hepatic sequelae may take up to 20 years, while the
latency for non-Hodgkin's lymphoma has not been
defined yet.
Some reasons for confidence in our results are that the
exposures hypothesised as at risk showed very similar
distributions to those reported in the European prospec-
tive cohorts based on hospital patients [36], and the
sequelae we found are among the most frequently
reported ones in previous related studies [1,21].
A few points require further elucidation. Firstly,
although the association between HCV infection and
non-Hodgkin's lymphoma has been clearly stated in an
Italian multicentre case-control study [37], we observed
Hepatic 84 305 535 2374 63 3
encephalopathy 1.5 8.4 5.5 4.2 - 7.0 7.4 1.2 6.4 5.8 - 7.0 0.5 0.0 13.9 4.7 - 33.5
Portal 40 172 261 1220 51 5
hypertension 4.0 0.9 4.6 3.2 - 6.5 3.6 0.6 6.1 5.3 - 7.0 0.4 0.0 25.4 7.2 - 73.5
extra-hepatic 28 432 132 1465 24 601
diseases 2.8 2.2 1.3 0.8 - 1.9 1.8 0.7 2.6 2.1 - 3.1 1.9 0.6 3.0 1.9 - 4.6
Cryoglobuli- 9 17 54 87 6 9
naemia†† 0.9 0.1 10.5 4.1 - 24.9 0.7 0.04 17.7 12.3 - 25.1 0.5 0.01 50.8 14.9 - 159
Non-Hodgkin 16 340 42 478 10 65
lymphoma 1.6 1.7 0.9 0.5 - 1.5 0.6 0.2 2.5 1.8 - 3.4 0.8 0.1 11.7 5.4 - 23.0
HCV+ had laboratory confirmation of the infection; nc = not computable;
† as reported in dialysis or hospital discharge registry;
§as reported in drug users registry or in hospital discharge registry;
**including syndromes due to both cirrhosis and portal hypertension.
Table 2: Prevalence and prevalence ratios of hepatic and extra-hepatic sequelae in HCV+ and HCV- by at-risk group, Lazio 
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no risk for non-Hodgkin's lymphoma in two at-risk
groups. The shorter survival of dialysis patients and the
older age of transfused patients than any other group
could explain these results, since both of them shortened
the disease latency. The second point involves the role of
age at infection. It has been reported that older age at
infection means a higher risk of cirrhosis [38]. The role
that age at infection plays in developing extrahepatic dis-
ease has been studied less than the role it plays in hepatic
disease. In our study, the risk of both hepatic and extrahe-
patic disease did not seem related to the age of infected
people, indeed sequelae showed high prevalence ratios in
the drug users who are likely to have been infected at very
young ages.
Further studies need to better understand the risk pro-
file of these diseases.
The final point concerns the stratification by at-risk
group we used to estimate the risk of sequelae associated
with HCV infection. This approach, in our opinion,
reduces the probability that the association between
infection and sequelae could be explained by exposure to
blood or by the initial disease causing the invasive proce-
dure, since both HCV-positive and HCV-negative people
in each at-risk group shared blood exposure and, in most
cases, the initial disease. Furthermore stratification by at-
risk group could also help to control confounding due to
behavioural or environmental factors if we hypothesise
that the life styles of people within the same at-risk group
is more homogeneous than in the general population.
Unfortunately, we did not have individual information on
factors known to be related to hepatic and extrahepatic
disease, such as alcohol for cirrhosis or benzene for lym-
phoproliferative disorders.
Limitations
Important sensitivity limitations may have affected the
prevalence estimates. The resultant underestimation is
bipartite: while it was possible to estimate the underre-
porting from laboratories, which allowed us to increase
our prevalence estimate from 1.24% to 1.56%, more
important sensitivity limitations derive from the number
of infections diagnosed prior to 1997 and those unde-
tected, which were estimated in Europe between 10% and
40% [39]. Moreover, although prevalence makes it possi-
ble to estimate the burden of chronic liver disease due to
HCV, information about virus genotypes would improve
this assessment and incidence is still the best indicator to
assess the dynamics of HCV infection and the impact of
prevention measures [40].
Other limitations affect this study. The possible mis-
classification of untested people who were classified as
HCV-negative may have resulted in underestimating the
relative risk of sequelae in HCV-positive subjects. We did
not explore the risk of HCV infection from combined
exposures as other authors have [9], or adjust the risk of
sequelae by analysing the other factors known to be
s t r o n g  p r e d i c t o r s  o f  h e p a t i c  s e q u e l a e ,  s u c h  a s  a l c o h o l
consumption or HIV-1 and HBV co-infections or envi-
ronmental exposures [2,6,21].
The most important limitation, however, is intrinsic to
the method used; the temporal relationship between
events can be accurately understood only by means of a
longitudinal prospective study.
Conclusions
The integrated data source approach improved the esti-
mate of HCV prevalence in at-risk groups; thanks to labo-
ratory data, it provides a more reliable estimate of HCV
infection sequelae in at-risk groups, despite longitudinal
approximation.
Our study 1) confirms that drug users and dialysis
patients have the highest risk of HCV infection; 2) shows
higher HCV prevalence in subjects with limited exposure
to blood, but the HCV is not conclusively attributable to
surgical procedures; 3) shows a decreasing trend of HCV
infection between 1997 and 2001 in all at-risk groups,
except for patients who had blood transfusions and
women who underwent obstetric surgery; 4) strengthens
the hypothesis of a high risk of hepatic diseases, cryo-
globulinaemia and non-Hodgkin's lymphoma associated
with HCV infection.
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